Level of middle mass molecules in synovial fluid of patients with rheumatoid arthritis

Authors

  • O.V. Syniachenko Donetsk National Medical University, Lyman, Ukraine
  • M.V. Yermolaieva Donetsk National Medical University, Lyman, Ukraine
  • T.Yu. Aliieva Donetsk National Medical University, Lyman, Ukraine
  • K.V. Lientsova Donetsk National Medical University, Lyman, Ukraine
  • S.M. Verzilov Donetsk National Medical University, Lyman, Ukraine
  • T.Yu. Syniachenko Donetsk National Medical University, Lyman, Ukraine

DOI:

https://doi.org/10.22141/1608-1706.6.21.2020.223884

Keywords:

rheumatoid arthritis, course, pathogenesis, synovial fluid, middle mass molecules

Abstract

Background. Due to direct contact with cartilage, bone surface and synoviocytes, the study of synovial fluid in rheumatoid arthritis has a great diagnostic value, and changes in its indicators clearly correlate with the data of the morphological study of the affected articular tissues. In the synovial fluid of rheumatoid arthritis patients, protein substances of diffe-rent molecular mass and enzymes involved in the destruction of cartilage, tendons and ligaments are accumulated. At the same time, there are no reliable differential diagnostic biomarkers of synovial fluid in joint pathology. The purpose and objectives of the study: to establish the clinical and pathogenetic significance of medium molecular weight compounds of different fractions in the synovial fluid of patients with rheumatoid arthritis, the relationship with physicochemical disorders in the synovial fluid and the composition of surfactants in it. Materials and methods. The synovial fluid obtained from the knee, elbow and shoulder joints was studied in 21 patients with rheumatoid arthritis (mean age 50 years, male to female ratio of 1 : 2), among whom mo-derate and high degree of disease activity was established in all cases, III and IV stages of pathological process — in 61.9 %, extra-articular form of the disease — in 61.9 %, systemic osteoporosis — in 95.2 %, seropositivity for rheumatoid factor (RF) — in 90.5 %, for cyclic citrulline peptide antibodies (CCPA) — in 95.2 % of patients. To determine the middle mass molecules in the synovial fluid and blood serum, a screening method was used with trichloroacetic acid precipitation of proteins and determination of the light absorption spectra by the acid-soluble fraction. Protein and non-protein nitrogenous surfactants were studied using an Olympus-AU640 bioanalyzer (Japan), and interfacial tensiometry with calculating the surface tension ratio at an infinite surface lifetime for high molecular weight substances and at a time of 0.01 s for low-molecular weight compounds (ST∞/0,01 %) was carried out using a computer apparatus ADSA-Toronto (Germany-Canada). Results. The integral composition of medium molecular weight compounds in synovial fluid and blood depends on serum levels of RF and CCPA, and the rates of progression of articular syndrome are associated with indicators of nucleotide (NF) and chromatophore fractions (CF) of middle mass molecules, which, along with aminopeptide (AF) and peptide fractions (PF), determine the high activity of the dise-ase, bone-destructive changes in the joints (AF), bone mineral density (AF, PF, CF), the formation of bone erosions (AF) and intra-articular chondromic bodies (NF, CF), directly correlate with the content of immunoglobulin G in the synovial fluid (NF, CF), and CF is directly correlated with the presence of arthrocalcifications and Hoffa’s fat pads. Conclusions. In rheumatoid arthritis, middle mass molecules of different fractions in the synovial fluid are involved in the disease pathogenesis, depend on clinical, radiological and sonographic signs of the disease, can be used to predict the course of the pathological process.

References

Dotsenko T.G., Shlikova G.I., Teplyakova O.V. The analysis of synovial fluid: clinical significance of derived results. Klin. Lab. Diagn. 2016. 61(8). 478-484. PMID: 30601639.

Oliviero F., Galozzi P., Ramonda R., de Oliveira F.L., Schiavon F., Scanu A. et al. Unusual findings in synovial fluid analysis: a review. Ann. Clin. Lab. Sci. 2017. 47(3). 253-259. PMID: 28667024.

Awisat A., Slobodin G., Jiries N., Rozenbaum M., Rimar D., Boulman N. et al. Pseudoseptic Arthritis with low synovial fluid glucose in familial mediterranean fever. Isr. Med. Assoc. J. 2017. 19(7). 461-462. PMID: 28786265.

Mahendran S.M., Oikonomopoulou K., Diamandis E.P., Chandran V. Synovial fluid proteomics in the pursuit of arthritis mediators: An evolving field of novel biomarker disco-very. Crit. Rev. Clin. Lab. Sci. 2017. 54(7–8). 495-505. doi: 10.1080/10408363.2017.1408561.

Baillet A., Trocme C., Romand X., Nguyen C.M.V., Courtier A., Toussaint B. et al. Calprotectin discriminates septic arthritis from pseudogout and rheumatoid arthritis. Rheumatology. 2019. 58(9). 1644-1648. doi: 10.1093/rheumatology/kez098.

Coiffier G., Ferreyra M., Albert J.D., Stock N., Jolivet-Gougeon A., Perdriger A. et al. Ultrasound-guided synovial ­biopsy improves diagnosis of septic arthritis in acute arthritis without enough analyzable synovial fluid: a retrospective analysis of 176 arthritis from a French rheumatology department. Clin. Rheumatol. 2018. 37(8). 2241-2249. doi: 10.1007/s10067-018-4160-9.

Manzo A., Bugatti S., Caporali R., Montecucco C. Histopathology of the synovial tissue: perspectives for biomarker development in chronic inflammatory arthritides. Reumatismo. 2018. 70(3). 121-132. doi: 10.4081/reumatismo.2018.1057.

Raza K., Scheel-Toellner D., Lee C.Y., Pilling D., Cur-now S.J., Falciani F. et al. Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis. Arthritis Res. Ther. 2016. 8(4). 120. doi: 10.1186/ar2009.

Hügle T., Kovacs H., Heijnen I.A., Daikeler T., Baisch U., Hicks J.M. et al. Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectro-scopy. Clin. Exp. Rheumatol. 2012. 30(2). 240-245. PMID: 22410098.

Zamani B., Jamali R., Ehteram H. Synovial fluid adenosine deaminase and high-sensitivity C-reactive protein activity in differentiating monoarthritis. Rheumatol. Int. 2012. 32(1). 183-188. doi: 10.1007/s00296-010-1602-3.

Peffers M.J., Smagul A., Anderson J.R. Proteomic analysis of synovial fluid: current and potential uses to improve clinical outcomes. Expert Rev. Proteomics. 2019. 16(4). 287-302. doi: 10.1080/14789450.2019.1578214.

Talabot-Ayer D., McKee T., Gindre P., Bas S., Baeten D.L., Gabay C. et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine. 2012. 79(1). 32-37. doi: 10.1016/j.jbspin.2011.02.011.

Adams S.B., Nettles D.L., Jones L.C., Miller S.D., Guyton G.P., Schon L.C. Inflammatory cytokines and cellular metabolites as synovial fluid biomarkers of posttraumatic ankle arthritis. Foot Ankle Int. 2014. 35(12). 1241-1249. doi: 10.1177/1071100714550652.

Altobelli E., Angeletti P.M., Piccolo D., De Angelis R. Synovial Fluid and serum concentrations of inflammatory markers in rheumatoid arthritis, psoriatic arthritis and osteoarthitis: a systematic review. Curr. Rheumatol. Rev. 2017. 13(3). 170-179. doi: 10.2174/1573397113666170427125918.

Hampel U., Sesselmann S., Iserovich P., Sel S., Paulsen F., Sack R. Chemokine and cytokine levels in osteoarthritis and rheumatoid arthritis synovial fluid. J. Immunol. Methods. 2018. 396(1–2). 134-139. doi: 10.1016/j.jim.2013.08.007.

Dickinson S.C., Vankemmelbeke M.N., Buttle D.J., Rosenberg K., Heinegard D., Hollander A.P. Cleavage of cartilage oligomeric matrix protein (thrombospondin-5) by matrix metalloproteinases and a disintegrin and metalloproteinase with thrombospondin motifs. Matrix Biol. 2013. 22(3). 267-278. doi: 10.1016/s0945-053x(03)00034-9.

Sheridan C. Low-molecular-weight albumin drug touted for severe osteoarthritis. Nat. Biotechnol. 2018. 36(4). 293. doi: 10.1038/nbt0418-293.

Xu H., Geddes R., Roberts-Thomson P.J. Low molecular weight IgM and CD5 B lymphocytes in rheumatoid arthritis. Ann. Rheum. Dis. 2004. 53(6). 383-390. doi: 10.1136/ard.53.6.383.

Meo Burt P., Xiao L., Hurley M.M. FGF23 Regulates Wnt/β-catenin signaling-mediated osteoarthritis in mice overexpressing high-molecular-weight FGF2. Endocrinology. 2018. 159(6). 2386-2396. doi: 10.1210/en.2018-00184.

Huang T.L., Hsu H.C., Yang K.C., Yao C.H., Lin F.H. Effect of different molecular weight hyaluronans on osteoarthritis-related protein production in fibroblast-like synoviocytes from patients with tibia plateau fracture. J. Trauma. 2019. 68(1). 146-152. doi: 10.1097/TA.0b013e3181a92cf8.

Downloads

Published

2021-04-05

Issue

Vol. 21 No. 6 (2020)

Section

Original Researches

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
  7. The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.